Cimzia (certolizumab pegol) / Astellas, UCB, Ferring - LARVOL DELTA

Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis. (PubMed, Biomedicines) - "There are many types of drugs to treat psoriasis: small-molecule drugs, including corticosteroids; retinoids; vitamin D analogs; and immunosuppressants, such as glucocorticoid ointment, tretinoin cream, methotrexate tablets, etc. Macromolecular biological drugs, such as Certolizumab, Secukinumab, Guselkumab, etc., include monoclonal antibodies that target various inflammatory signaling pathways...Spesolimab is the latest biological agent used to target the interleukin-36 receptor (IL-36R) to be approved for market use, which significantly reduces the risk of general pustular psoriasis (GPP) flare by 84%...In this review, we analyze the current status of psoriasis therapeutics and discuss novel delivery systems for diverse psoriasis drugs, as well as emerging cell-based therapies. We also summarize the therapeutic effectiveness of different delivery strategies."

Journal • Review • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Data-Based Lumping and Splitting of Treatments in Network Meta-Analysis in the Presence of Heterogeneity: A Flexible Non-Parametric Bayesian Approach (ISPOR 2025) - "We illustrate these methods in an application to the certolizumab baseline risk adjustment example from NICE TSD 3. Node lumping differed under the unadjusted and adjusted models, with two groups in the former and three in the latter. Data-based lumping/splitting decisions informed by prior expectation of unique treatments is feasible to implement within existing NICE TSD code. Lumped treatments can differ significantly in adjusted compared to unadjusted models."

Heterogeneity • Retrospective data

Identify the Adverse Drug Reactions Among Rheumatoid Arthritis Patients Being Administered Specific Classes of Disease-Modified Anti-Rheumatic Drugs (DMARDs) (ISPOR 2025) - "The medications Baricitinib, Tofacitinib, and Upadacitinib were analyzed for the JAK inhibitors; the medications Adalimumab, Certolizumab, Etanercept, Golimumab, and Infliximab were analyzed for the TNF-alpha blockers; and the medications Hydroxychloroquine, Leflunomide, Methotrexate, and Sulfasalazine were analyzed for the conventional DMARDs. The TNF-alpha blockers had more reports of ADRs in general, but JAK inhibitors were the most likely to be the primary suspect if they were associated with an adverse drug event. The results show that the conventional DMARDs had the least amount of total reported primary suspect ADRs compared to JAK inhibitors and TNF-alpha blockers."

Adverse drug reaction • Clinical • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients. (PubMed, Crohns Colitis 360) - "In comparison to White patients, Black patients with CD were less likely to receive advanced therapies; Adalimumab (adjusted odds ratio- aOR 0.89), Certolizumab (0.81), Vedolizumab (0.66), Ustekinumab (0.82), or Tofacitinib (0.58). Black patients with UC were less likely to receive advanced therapies; Adalimumab (0.83), Golimumab (0.62), Vedolizumab (0.69), Ustekinumab (0.73), or Tofacitinib (0.55)...There were racial disparities in IBD medical therapy and disease outcomes. Black IBD patients had lower treatment with advanced therapies, higher opioid and corticosteroid use, and higher IBD-related complications."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis. (PubMed, BMC Rheumatol) - "Our results indicate that transitional and CD21- PD-1+ B cells are associated with remission in early RA."

IO biomarker • Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CD21 • PD-1

Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review. (PubMed, Arthritis Care Res (Hoboken)) - "There is heterogeneity in formulation of guidelines on the use of DMARDs in pregnancy. Recommendations for csDMARDs were similar between guidelines. There was significant variability in recommendations for b/tsDMARD use, reflecting current minimal literature in this area."

Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Lupus • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Systemic Lupus Erythematosus

Triple Biologic Therapy for Refractory Crohn's Disease. (PubMed, J Crohns Colitis) - "Triple biologic therapy remains experimental and should be approached with caution, pending more robust evidence. Larger and translational studies are needed to better identify patients who may benefit, define optimal combinations, and clarify long-term safety of these combinations."

Journal • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis

A Case of Rectus Sheath Hematoma Caused by Self-Injection of Certolizumab Pegol. (PubMed, Cureus) - "This is the first reported case of RSH caused by certolizumab pegol. Factors contributing to RSH include low abdominal wall fat, the use of auto-injector-based preparations, and anticoagulant use in dialysis."

Journal • Chronic Kidney Disease • Hematological Disorders • Immunology • Inflammatory Arthritis • Nephrology • Pain • Renal Disease • Rheumatoid Arthritis • Rheumatology

Discontinuation vs. continuation of concomitant methotrexate in patients with rheumatoid arthritis on certolizumab pegol: results from a randomised, controlled trial. (PubMed, Arthritis Res Ther) - "Discontinuing concomitant MTX in RA patients on CZP is clinically feasible for maintaining LDA."

Clinical • Journal • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis. (PubMed, Innate Immun) - "Non-tumor necrosis factor inhibitors (Non-TNFi) such as abatacept, rituximab, tocilizumab, and sarilumab are examples, as are anti-tumor necrosis factor (TNF) medications such as infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol. The assessment of RA treatment response typically combines patient-reported outcomes, physical evaluations, and laboratory findings, as there isn't a single biomarker that has proven sufficient for measuring disease activity. This review explores the usage of biologic DMARDs as a therapeutic approach for RA, as well as the biomarkers typically used for RA early diagnosis, prognosis prediction, and disease activity evaluation."

Biomarker • Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

ARE ANTI-TNF MEDICATIONS RELATED TO HEART FAILURE? A STUDY OF THE FAERS DATABASE - Yousef Al-Mabrouk (ACC 2025) - "We aim to assess the association of heart failure and anti-TNF medications. We searched the United States Food and Drug Adminstration Adverse Event Report System (FAERS) for heart failure associated with the use of Etanercept, Infliximab, Adalimumab, Certolizumab pegol, and Golimumab in the past 10 years. Patients taking anti-TNF drugs might have an increased risk of developing heart failure. Further research is required to confirm this association."

Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology • ROR1

Real-Life Analysis of Therapeutic Management and Its Correlation with the Dermatology Life Quality Index Score in 108 Patients with Pustular Psoriasis: An Italian Monocenter Study. (PubMed, Dermatol Pract Concept) - "Currently, systemic conventional therapy remains the therapeutic fulcrum of PP management. A great effect on QoL, especially for GPP+PSO, was assessed regardless the ongoing treatment and only newer biologic options were able to somehow positively impact."

Journal • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. (PubMed, Curr Issues Mol Biol) - "A significant decrease in SUA levels was noticed, especially in patients treated with IL-17 inhibitors. Further studies should identify which bDMARD is the most potent in the lowering of SUA levels. bDMARDs were efficient in PsA disease activity."

Journal • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reports (FAERS) for drug-induced sinusitis. (PubMed, Expert Opin Drug Saf) - "Following the validation of drug-related risks, a total of 13 medications were ultimately identified, including TNF inhibitors: pomalidomide (ROR: 14.77), certolizumab pegol(ROR: 8.21), etanercept (ROR: 7.961), lenalidomide (ROR: 6.998), adalimumab (ROR: 6.677), infliximab (ROR: 3.939); C4B-targeted drugs: human immunoglobulin G (ROR:3.846) and other risk drugs were commonly reported. Co-localization analysis and MR analysis suggests associations between TNF, C4B, and LTA and sinusitis. We demonstrated the risk of sinusitis associated with 13 drugs, including pomalidomide, and the impact of TNF and C4B drugs on sinusitis, which provides guidance for the use of related drugs and the prevention of sinusitis."

Adverse events • Journal • Immunology • Inflammatory Arthritis • Otorhinolaryngology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Sinusitis

Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS). (PubMed, Expert Opin Drug Saf) - "Compared with infliximab, certolizumab pegol, and adalimumab, golimumab showed the strongest signal. The strongest signal corresponding to appendicitis, pulmonary tuberculosis, pneumonia, sepsis, urinary tract infection, otitis media and herpes zoster is golimumab, infliximab, golimumab, natalizumab, certolizumab pegol, infliximab and infliximab...Compared with other TNF-α inhibitors, golimumab has the strongest infectious toxicity signal. When using TNF-α inhibitors to treat IBD, infection-related AEs should be vigilant."

Adverse events • Journal • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Nephrology • Oncology • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock • Tuberculosis • Varicella Zoster • IL12A

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single arm, open-label, phase 2 trial (EULAR 2025) - No abstract available

Adverse events • Clinical • P2 data • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis

Tonsillar Tuberculosis Occurring After Certolizumab Treatment for Rheumatoid Arthritis: A Case Report (EULAR 2025) - No abstract available

Case report • Clinical • Immunology • Infectious Disease • Inflammatory Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Tuberculosis

Discontinuation vs. continuation of concomitant methotrexate in patients with rheumatoid arthritis on certolizumab pegol: Results from a randomized, controlled trial (EULAR 2025) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Certolizumab-Induced Urticarial Vasculitis: A Case Report. (PubMed, Curr Drug Saf) - "With the increasing use of CZ, physicians should be aware of the possibility of UV associated with CZ."

Journal • Dermatology • Dermatopathology • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Urticaria • Vasculitis

Rheumatoid Factor Predicts Long-Term Retention Associated With Effectiveness of Certolizumab Pegol in Patients With Rheumatoid Arthritis: A Two-Center Retrospective Study. (PubMed, Int J Rheum Dis) - No abstract available

Journal • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Rural-urban disparities in the use of targeted and non-targeted systemic medications for inflammatory dermatologic conditions: A DataDerm study (AAD 2025) - " Urban patients were more likely to receive any targeted systemic therapy (OR: 1.44, p0.05). Prescribing patterns of targeted and non-targeted systemic therapies for chronic inflammatory skin diseases highlight disparities between rural and urban communities, particularly among FDA-approved biologics and JAK inhibitors. Whether such disparities are due to barriers in accessing dermatologic care or other factors warrants further research (4)."

Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Psoriasis

Neonatal Inflammatory Skin and Bowel Disease 1 (NISBD1): A Case of ADAM17 Homozygous Mutation (AAD 2025) - "Topical triamcinolone, zinc oxide paste, and emollients have improved but not resolved his skin. This case illustrates the presentation of NISBD1, including chronic diarrhea, FTT, pustular rash, and recurrent infections. Treatment with certolizumab and ustekinumab has been reported to improve cutaneous symptoms."

Clinical • Candidiasis • Dermatology • Gastrointestinal Disorder • Genetic Disorders • Infectious Disease • Inflammatory Bowel Disease • Pediatrics • Small for Gestational Age • ADAM17

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth (PRNewswire) - "Net sales were up by 15% to € 5.61 billion (+17% CER1) driven by a strong, triple- and double-digit growth performance of newly launched growth drivers: BIMZELX, EVENITY, FINTEPLA, RYSTIGGO and ZILBRYSQ as well as solid contribution from CIMZIA and BRIVIACT reaching its peak sales two years ahead of target...EVENITY (romosozumab) since launch globally reached more than 900 000 (2023: 600 000) women living with postmenopausal osteoporosis at high risk of fracture. Net sales in Europe increased by 71% to € 103 million (+71% CER) after € 60 million in 2023...BRIVIACT (brivaracetam) was used by over 232 000 people living with epilepsy and increased net sales to € 686 million, achieving its peak sales target of 'at least € 600 million' well before 2026."

Sales • Sales projection • Ankylosing Spondylitis • Crohn's disease • Epilepsy • Hidradenitis Suppurativa • Inflammatory Arthritis • Myasthenia Gravis • Osteoporosis • Psoriasis • Psoriatic Arthritis • Pustular Psoriasis • Rheumatology • Spondylarthritis

Certolizumab enhances spinal cord injury recovery in rats through inhibition of the TNF-α signaling pathway and neuronal apoptosis. (PubMed, Inflammopharmacology) - "Certolizumab treatment exerts a neuroprotective effect against secondary damage in SCI through the inhibition of neuroinflammation and apoptosis."

Journal • Preclinical • CNS Disorders • Inflammation • Orthopedics • CASP3 • IL6 • TNFA

Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database. (PubMed, Sci Rep) - "Using the Standardized MedDRA Query (SMQ), adverse drug reaction (ADR) reports related to SLE of infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol were collected from the FAERS database starting from the data retrieval quarter up to the fourth quarter of 2023. This suggests that different TNF-α inhibitors should be continuously monitored for SLE-induced complications in clinical practice, and that appropriate drug management should be carried out for different patients. Further research is necessary to validate our findings."

Journal • Real-world evidence • Cardiovascular • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Oncology • Respiratory Diseases • Rheumatology • Systemic Lupus Erythematosus